[Treatment of medium-severe essential XXXX with beta-Aldopur under practice conditions].

@entity1 @entity101 @entity44487 @entity7206 @entity972 @entity1368 @entity1371 @entity1482
23 @entity101 @entity1 were treated with the new fixed-dose combination drug Beta-Aldopur, containing 100 mg @entity44487 and 50 mg @entity1482 per tablet. In part they had been pretreated with other fixed combinations without sufficient success. 19 @entity1 completed the eight-week study. Initial dosage of two tablets could be reduced to one tablet daily following normalization (less than 90 mm Hg) of diastolic blood pressure in one third of @entity1 . Mean pressure in a sitting posture was lowered from 176 +/- 21/111 +/- 9 mm Hg to 156 +/- 21/93 +/- 8 mm Hg (p less than 0,0001) gradually until the 4th week. Body weight decreased by 2.5 kg (3.1%) until the 6th week and remained constant thereafter. Mean concentration of serum @entity972 rose significantly by 0.42 mmol/l within normal limits. Specific and non-specific side effects were very rare and no serious reactions occurred. Compared to pretreatment with other fixed combinations, most of them containing @entity7206 , the combination of @entity44487 with @entity1482 was more efficacious in lowering the blood pressure. According to the results of our study Beta-Aldopur is suitable for treatment of essential @entity101 of all degrees, especially for @entity1 prone to @entity1371 , if secondary @entity1368 caused by @entity101 or by medication may be expected and/or if other medications are not adequately effective.
